Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424630 | 0.78 | MAPT (0.48) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL25263910 | 0.75 | MAPT (0.51) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL1416056 | 0.72 | MAPT (0.67) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL25304250 | 0.72 | MAPT (0.36) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| Hydrochloric Acid SCHEMBL30660614 | 0.71 | MAPT (0.50) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL19649847 | 0.71 | ALDH1A1 (0.41) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL4140567 | 0.70 | SCN10A (0.43) | LMNAALDH1A1KLKB1CACNA1H | |
| SCHEMBL15520076 | 0.70 | MAPT (0.63) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL15520670 | 0.70 | MAPT (0.68) | MAPTLMNAALDH1A1PKML3MBTL1 | |
| SCHEMBL29177180 | 0.70 | ALDH1A1 (0.43) | MAPTLMNAALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210694-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416227-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | MAPT 781/4885LMNA 2426/4885ALDH1A1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.